Growth Scale Values Are Gaining Traction in Clinical Trials
Growth scale values (GSVs) have gained traction as a more precise option for measuring outcomes in clinical trials.
read morePharma Research and Content
Pearson has a wide range of Clinical Outcome Assessments (COAs) that measure primary and secondary symptoms related to cognitive/neurocognitive functioning, dementia/Alzheimer's, behavioral and mental health concerns, and other factors affecting a patients’ quality of life. Each has been proven to be reliable through decades of research and is suitable for a wide range of ages with norms reflective of today’s diverse population.
Discover how our COAs are being used in clinical research, access webinars featuring experts in the field, read our blog, or review our newsletter curated with relevant industry-related content.
Blogs
-
-
Taking an innovative approach to challenging COA translations
Over the last ten years, the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-3), a leading developmental assessment for children ages 1–42 months, has been referenced as an endpoint in 145 clinical trials (Citeline, 2024). Of those, 6.21% have included sites in the Finno-Ugric countries of Estonia, Finland, and Hungary.
read more
Webinars
Testing cognition in clinical drug trials for Alzheimer's disease
featuring Dr. John Harrison
The number of adults living with Alzheimer’s disease (AD) is expected to top 14 million by 2060. Not only is there no cure at this point, but current treatments haven’t been successful, and clinical trials to develop new therapeutic interventions keep failing. What’s holding back novel treatment option breakthroughs? Watch this webinar for insight into why assessment tools fail, strategies for selecting appropriate scales, and how better endpoint measures can help advance AD research.
Finding the best metrics for pediatric neurogenetic trials
featuring Dr. Shapiro, Dr. Eisengart, and Dr. Harmatz
Neurogenetic disorders that impact how the brain functions affect up to three percent of children, but available evaluation tools aren’t sensitive enough to detect change in their developmental skills. This poses a challenge for clinical trial sponsors who are trying to assess potential treatments. Gain more expert insight into the difficulties associated with therapy in these trial settings.
